Want to find out more about how we can help support your patient services? Find out more here.
Analysis of the molecular landscape that characterises a patient or disease is an evolving area that is increasingly driving discoveries in healthcare.
Haemophilia is a lifelong genetic disorder characterised by excessive bleeding.(1) Despite the existence of treatments for haemophilia, the condition continues to have major impacts on quality of life, for example in the areas of pain (acute and chronic), joint mobility, and physical function.(1) To mark World Haemophilia Day on 17 April, Prime Patient partnered with sister agency HCD Economics, a consultancy specialising in haemophilia patient research, and haemophilia advocate Laurence Woollard to better understand the existing relationship between patients and industry and how meaningful improvements can be made to the lives of people living with haemophilia (PwH).
Prime Patient team up with Jess Duggan from the SynGAP Research Fund to better understand what this advocacy group wants Pharma to know this Developmental Disabilities Awareness Month.